Combining IL-2-based immunotherapy with commensal probiotics produces enhanced antitumor immune response and tumor clearance

BACKGROUND: Interleukin-2 (IL-2) serves as a pioneer of immunotherapeutic agent in cancer treatment. However, there is a considerable proportion of patients who cannot benefit from this therapy due to the limited clinical responses and dose-limiting toxicities. Mounting evidence indicates that comme...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Immunother Cancer
Main Authors: Shi, Linlin, Sheng, Jianyong, Chen, Guozhong, Zhu, Peng, Shi, Changping, Li, Bei, Park, Chaiwoo, Wang, Jingyi, Zhang, Bixiang, Liu, Zhi, Yang, Xiangliang
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2020
Assuntos:
Basic Tumor Immunology
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7542661/
https://ncbi.nlm.nih.gov/pubmed/33028692
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-000973
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados